The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

By M. Solèr, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, G. Cioppa. European Respiratory Journal, 2001

854 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Physiology

View Paper: https://www.semanticscholar.org/paper/26603f1f692a8bf50abd26b8371ef43454e3dfeb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Humbert
2. R. Beasley
3. J. Ayres
4. S. Hedgecock
5. H. Fox
6. K. Beeh
7. S. Ramos
8. J. Hebert

Citations in the corpus

• Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE (2005, methodology): “Diary cards were used to record the clinical symptom score, PEF and use of rescue medication (14).”